Literature DB >> 30442738

Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.

Mark A Helvie, Therese B Bevers.   

Abstract

Breast cancer remains the most common nonskin cancer among women and a leading cause of morbidity and mortality. Early detection through screening and advances in treatment have contributed to a 39% mortality reduction in the United States since 1990. The NCCN Guidelines for Breast Cancer Screening and Diagnosis recommend annual mammographic screening for average-risk women beginning at age 40 years. Mammographic screening and subsequent treatment reduces breast cancer mortality based on a wide range of studies. This article highlights NCCN's position on screening mammography and the screening controversy.
Copyright © 2018 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2018        PMID: 30442738     DOI: 10.6004/jnccn.2018.7081

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  11 in total

1.  Variation in Breast Cancer Screening Recommendations by Primary Care Providers Surveyed in Wisconsin.

Authors:  Emily Nachtigal; Noelle K LoConte; Sarah Kerch; Xiao Zhang; Amanda Parkes
Journal:  J Gen Intern Med       Date:  2020-06-03       Impact factor: 5.128

2.  Breast cancer screening in average-risk women: towards personalized screening.

Authors:  Almir Gv Bitencourt; Carolina Rossi Saccarelli; Christiane Kuhl; Elizabeth A Morris
Journal:  Br J Radiol       Date:  2019-09-23       Impact factor: 3.039

3.  External validation of AI algorithms in breast radiology: the last healthcare security checkpoint?

Authors:  Teodoro Martin-Noguerol; Antonio Luna
Journal:  Quant Imaging Med Surg       Date:  2021-06

4.  "It's something I'll do until I die": A qualitative examination into why older women in the U.S. continue screening mammography.

Authors:  Laura E Brotzman; Rachel C Shelton; Jessica D Austin; Carmen B Rodriguez; Mariangela Agovino; Nathalie Moise; Parisa Tehranifar
Journal:  Cancer Med       Date:  2022-05-26       Impact factor: 4.711

5.  Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.

Authors:  Jean L Wright; Habib Rahbar; Samilia Obeng-Gyasi; Ruth Carlos; Judy Tjoe; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2021-11-23       Impact factor: 50.717

Review 6.  Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review.

Authors:  Wendie A Berg; Elizabeth A Rafferty; Sarah M Friedewald; Carrie B Hruska; Habib Rahbar
Journal:  AJR Am J Roentgenol       Date:  2020-12-23       Impact factor: 3.959

7.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

8.  Effects of a WhatsApp-Delivered Education Intervention to Enhance Breast Cancer Knowledge in Women: Mixed-Methods Study.

Authors:  Antonio Augusto Claudio Pereira; Juliana Regina Destro; Marcelo Picinin Bernuci; Lucas França Garcia; Tiago Franklin Rodrigues Lucena
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-21       Impact factor: 4.773

9.  Landscape of the Peripheral Immune Response Induced by Local Microwave Ablation in Patients with Breast Cancer.

Authors:  Wenbin Zhou; Muxin Yu; Xinrui Mao; Hong Pan; Xinyu Tang; Ji Wang; Nan Che; Hui Xie; Lijun Ling; Yi Zhao; Xiaoan Liu; Cong Wang; Kai Zhang; Wen Qiu; Qiang Ding; Shui Wang
Journal:  Adv Sci (Weinh)       Date:  2022-04-11       Impact factor: 17.521

Review 10.  Surgical Management of Hereditary Breast Cancer.

Authors:  Elizabeth R Berger; Mehra Golshan
Journal:  Genes (Basel)       Date:  2021-08-31       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.